Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

cetirizine (Rx, OTC)Brand and Other Names:Zyrtec, Zyrtec Allergy, more...Children's Zyrtec Allergy, Children's Zyrtec Hives Relief, PediaCare Children's 24 Hour Allergy, Aller-Tec, Wal-Zyr

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 5mg
  • 10mg

tablet, oral-disintegrating

  • 10mg

tablet, chewable

  • 5mg
  • 10mg

syrup

  • 5mg/5mL

solution

  • 5mg/5mL
more...

Allergies/Hay Fever/Urticaria

Perennial and seasonal allergic and vasomotor rhinitis; relief of symptoms from colds, urticaria, angioedema, anaphylactic reactions, pruritus, allergic conjunctivitis

5-10 mg PO qDay, depending on severity of symptoms; not to exceed 10 mg qDay

Dosing Modifications

Renal impairment

  • GFR >50 mL/min: Dose adjustment not necessary
  • GFR ≤ 50 mL/min: 5 mg PO qDay
  • Peritoneal dialysis: 5 mg PO qDay
  • Intermittent hemodialysis: 5 mg PO qDay; may also administer 3 times weekly

Hepatic impairment

  • Dose adjustment not provided by manufacturer's label

Administration

May be taken with or without food

Dosage Forms & Strengths

tablet

  • 5mg
  • 10mg

tablet, oral-disintegrating

  • 10mg

tablet, chewable

  • 5mg
  • 10mg

syrup

  • 5mg/5mL

solution

  • 5mg/5mL
more...

Allergies/Hay Fever/Urticaria

Perennial and seasonal allergic and vasomotor rhinitis

<2 years: Safety and efficacy not established

2-6 years: 2.5 mg (0.5 teaspoon) oral solution PO qDay; can increase to 5 mg PO qDay or 2.5 mg PO twice daily; not to exceed 5 mg qDay

>6 years: 5-10 mg PO qDay, depending on severity of symptoms; not to exceed 10 mg qDay

Dosing Modifications

Renal impairment

  • GFR ≥30 mL/min/1.73 m²: Dose adjustment not necessary
  • GFR 10-29 mL/min/1.73 m²: Decrease dose by 50%
  • GFR < 10 mL/min/1.73 m²: Not recommended
  • Intermittent hemodialysis or peritoneal dialysis: Decrease dose by 50%

Hepatic impairment

  • Dose adjustment not provided by manufacturer's label

Administration

May be taken with or without food

5 mg PO qDay; may increase to 10 mg/day mazimum, depending on severity of symptoms; not to exceed 5 mg qDay in patients >77 years

Next

Interactions

Interaction Checker

cetirizine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Somnolence (2-14%)

            Headache (11-14%)

            1-10%

            Fatigue (5.9%)

            Dry mouth (5%)

            Dizziness (2%)

            Diarrhea (2-3%)

            Malaise (4%)

            Bronchospasm (2-3%)

            Vomiting (2-3%)

            Epistaxis (2-4%)

            <1%

            Stomach pain

            Drowsiness

            Angioedema

            Fussiness

            Hallucinations

            Hypotension

            Tremor

            Tongue discoloration

            Previous
            Next

            Warnings

            Contraindications

            Documented hypersensitivity to cetirizine, hydroxyzine

            Cautions

            Avoid alcohol, sedatives, and tranquilizers, due to increased risk of drowsiness

            May cause CNS depression; avoid activities requiring mental alertness until accustomed to medication

            Use caution in hepatic and renal impairment

            The elderly may be more sensitive to adverse effects

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: B; C for Zyrtec-D 12 Hour

            Lactation: Excreted in breast milk; use not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Histamine H1-receptor antagonist; competes with histamine on effector cells in the gastrointestinal tract, blood vessels and respiratory tract

            Absorption

            Peak plasma concentration: 114 ng/mL

            Peak serum time: 1 hr

            Duration: >24 hr ( suppression of skin wheal and flare reactions

            Distribution

            Protein bound: 93%

            Vd: 0.56 L/kg

            Metabolism

            Metabolism: Liver; low first pass

            Limited extent by oxidative O-dealkylation to inactive metabolite

            Elimination

            Half-life: 7.9hr

            Excretion: Urine (70%); feces (10%)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.